TD Cowen Initiates Coverage On Opus Genetics with Buy Rating

Benzinga Newsdesk www.benzinga.com Neutral 67.8%

Neg 0% Neu 67.8% Pos 0%

TD Cowen analyst Ritu Baral initiates coverage on Opus Genetics (NASDAQ:IRD) with a Buy rating.

Comments

No comments yet. Be the first!